CASE REPORT

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis

H Biering¹, B Saller⁴,*, J Bauditz¹, M Pirlich¹, B Rudolph², A Johne¹, M Buchfelder⁵,*, K Mann⁶,*, M Droste⁷,*, I Schreiber⁴, H Lochs¹ and C J Strasburger¹,*

¹Department of Gastroenterology, Hepatology and Endocrinology, ²Institute of Pathology and ³Institute for Clinical Pharmacology, Charité-Universitätsmedizin Berlin, 4Division of Endocrinology, Department of Medicine, University of Duisberg-Essen, Germany and 5Department of Neurosurgery, University Hospital, Erlangen, Germany, ⁶Division of Endocrinology, Department of Medicine, University of Duisberg-Essen, Germany and ⁷Oldenburg, Germany

(Correspondence should be addressed to C J Strasburger, Division of Clinical Endocrinology, Department of Medicine, Charité-Universitätsmedizin Berlin, Schumannstr. 20/21, 10117 Berlin, Germany; Email: Christian.Strasburger@charite.de)

*On behalf of the German pegvisomant investigators

Abstract

Objective: The new GH receptor antagonist pegvisomant is the most effective medical therapy to normalize IGF-I levels in patients with acromegaly. Based on currently available data pegvisomant is well tolerated; however, treatment-induced elevation of transaminases has been reported and led to the necessity for drug discontinuation in some patients in the pivotal studies. The aim of this study was to evaluate and characterize the prevalence of elevated transaminases and to describe in detail the findings in a single case who required drug discontinuation because of elevation of transaminases which emerged during treatment and who underwent liver biopsy.

Design and methods: Retrospective safety analyses were carried out on 142 patients with acromegaly receiving pegvisomant treatment in Germany between March 2003 and the end of 2004. Of these patients, 123 were documented in a post-marketing surveillance study, one case of elevated transaminases was reported spontaneously and the other patients were treated in a clinical study.

Results: Mean treatment duration with pegvisomant in the ongoing observational study at the end of 2004 was 28.3 ± 19.9 (S.D.) weeks. Twelve out of the 142 patients had elevated transaminases above three times the upper limit of normal, likely caused by biliary obstruction in five of the patients. All patients but one affected by elevated transaminases had been previously treated with somatostatin analogues. In six out of 142 (4%) of patients, pegvisomant was permanently withdrawn because of elevated transaminases. The same number of patients showed a transient increase of transaminases with either spontaneous remission without dose modification (n = 4) or no re-increase of transaminases after temporary discontinuation and re-exposure (n = 2). The liver biopsy of one patient who was permanently withdrawn showed a chronic mild hepatitis with a mixed portal inflammation including eosinophilic granulocytes.

Conclusions: Liver function tests should be regularly followed on pegvisomant treatment. Biliary complications, which may arise from restitution of normal gall bladder motility after cessation of somatostatin analogue treatment, need to be differentiated from pegvisomant-induced abnormalities. The histological pattern of the liver biopsy performed in one of the patients showed a mild chronic active hepatitis. The lack of dose dependency and rather low frequency of elevated transaminases in those cases where a biliary disorder was excluded render this reaction an idiosyncratic drug toxicity.

European Journal of Endocrinology 154 213–220

Introduction

Acromegaly is a debilitating condition, characterized by excess of growth hormone (GH) from a pituitary tumour. Average life expectancy in patients with active acromegaly is reduced by approximately 10 years and cardiac disease is the principal cause of premature death. Treatment goals include relieving clinical symptoms, normalizations of biochemical markers, control of tumour mass and preservation/restoration of pituitary function. Adequate control of GH and insulin-like growth factor-I (IGF-I) levels results in normalization of life expectancy.
Elevations of transaminases during pegvisomant treatment

Up to the end of 2004, 35 acromegallic patients have been treated in Germany with pegvisomant within clinical trials and 123 acromegallic patients have been included in a non-interventional post-marketing surveillance study (including 17 patients who had already participated in a clinical trial before entering the non-interventional surveillance study). In addition, patients with active acromegaly have been on the commercial drug without being included in clinical trials.

Up to December 2004 there have been reports of elevated transaminases to more than three times the upper limit of normal (ULN) in 12 patients (seven males, five females, age 44±9 years). Four cases were reported as adverse events from clinical trials, six cases from the non-interventional surveillance study and two were reported spontaneously from patients not included in either. Table 1 summarizes the characteristics as well as the clinical and biochemical data of these 12 patients. Alkaline phosphatase and bilirubin levels were available from only a minority of these patients. An increased level of bilirubin to 2.1-fold ULN was seen in patient no. 1. Elevated alkaline phosphatase levels were seen in patients no. 2 and no. 9 (1.4- and 1.7-fold ULN respectively).

There was one case of elevated transaminases 80.6 weeks after initiation of pegvisomant treatment. In the other 11 patients, the interval between start of pegvisomant and onset of elevated transaminases was between 6.4 and 34.7 weeks (15.7±10.7 weeks, means±S.D.). The dosage of pegvisomant at the onset of transaminases abnormalities was between 10 and 25 mg/day (15±5 mg/day). Ten out of the twelve patients had previously received Sandostatin LAR (Novartis Pharma, Basel, Switzerland) as medical therapy, except for patient no. 6 who received subcutaneous octreotide and patient no. 10 who was not pretreated with somatostatin analogues. At the time of elevated transaminases, two patients were receiving a combination of pegvisomant with 30 mg long-acting octreotide every 4 weeks within a clinical trial (patients no. 8 and no. 9). Two patients had discontinued Sandostatin LAR for more than 2 years (patients no. 11 and no. 12), in six other patients the last dose of Sandostatin LAR was given between 7 and 36 weeks before the elevated transaminases.

In five patients (patient nos 1, 2, 9, 11 and 12), sonographically proven gallstone disease was present together with elevated levels of γ-GT and/or alkaline phosphatase or bilirubin; in patient no. 6 with sonographically proven gallstones these laboratory data were unavailable. In two of these patients (patients no. 9 and no. 12), bile duct stones could be verified by endoscopic retrograde cholangiography as the most obvious reason for laboratory abnormalities, suggesting biliary complications rather than a drug reaction as the reason for liver enzyme elevations. Additionally, in patient no. 2 the leading enzyme was γ-GT and gallstones were found.

During follow-up, transaminases returned to normal in all patients after 4–32 weeks (mean 12 weeks). Interestingly, in four patients, transaminases spontaneously normalized despite ongoing treatment with pegvisomant.

Case study

We report here in detail on a 43-year-old man (Table 1, patient no. 8) who presented in May 1997 in our clinic with typical clinical features of acromegaly and an elevated IGF-I. Magnetic resonance imaging demonstrated a macroadenoma of the pituitary gland with suprasellar extension. Debulking of the tumour by trans-sphenoidal surgery in June 1997 as well as stereotactic radiotherapy of the residual pituitary adenoma in 1999/2000 effectively reduced tumour mass but was not sufficient to control the GH excess. Using several medications (lanreotide, dopamine agonists), only transient and partial suppression of the residual acromegaly disease activity was achieved. Long-acting octreotide

www.eje-online.org
## Table 1 Clinical and biochemical characteristics of 12 patients with elevation of liver function tests (LFT) during pegvisomant treatment.

<table>
<thead>
<tr>
<th>#</th>
<th>Patient no.</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Time between last dose of long-acting octreotide and LFT elevation (weeks)</th>
<th>Time between start of pegvisomant and LFT elevation (weeks)</th>
<th>Pegvisomant dose at onset of LFT elevation (mg/day)</th>
<th>Peak LFT elevation</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>41</td>
<td>21.6</td>
<td>15.6</td>
<td>10</td>
<td>25.7</td>
<td>20.2</td>
<td>4.6</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>55</td>
<td>7.6</td>
<td>2.3</td>
<td>10</td>
<td>4.9</td>
<td>—</td>
<td>8.7</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>27</td>
<td>21.0</td>
<td>8.9</td>
<td>15</td>
<td>4.7</td>
<td>3.3</td>
<td>—</td>
</tr>
<tr>
<td>4**</td>
<td>F</td>
<td>40</td>
<td>12.0</td>
<td>7.3</td>
<td>10</td>
<td>9.8</td>
<td>4.1</td>
<td>7.6</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>46</td>
<td>23.1</td>
<td>12.3</td>
<td>15</td>
<td>3.8</td>
<td>0.9</td>
<td>3.1</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>31</td>
<td>34.7*</td>
<td>34.7</td>
<td>20</td>
<td>10.9</td>
<td>2.9</td>
<td>—</td>
</tr>
<tr>
<td>7**</td>
<td>F</td>
<td>45</td>
<td>35.7</td>
<td>27.0</td>
<td>25</td>
<td>3.6</td>
<td>2.0</td>
<td>1.7</td>
</tr>
<tr>
<td>8***</td>
<td>M</td>
<td>43</td>
<td>Continued***</td>
<td>9.0</td>
<td>10</td>
<td>4.9</td>
<td>3.1</td>
<td>—</td>
</tr>
<tr>
<td>9***</td>
<td>F</td>
<td>44</td>
<td>Continued***</td>
<td>8.9</td>
<td>15</td>
<td>20.8</td>
<td>11.1</td>
<td>—</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>53</td>
<td>No previous octreotide</td>
<td>12.7</td>
<td>15</td>
<td>4.5</td>
<td>2.7</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>42</td>
<td>108</td>
<td>80.6</td>
<td>25</td>
<td>3.1</td>
<td>2.7</td>
<td>6.7</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>61</td>
<td>177</td>
<td>6.4</td>
<td>15</td>
<td>4.0</td>
<td>2.1</td>
<td>5.1</td>
</tr>
</tbody>
</table>

*ALT, AST, γ-GT, g-glutamyltranspeptidase.
** Patients received concomitant medications which are potentially hepatotoxic.
*** Patients were treated with a combination of daily pegvisomant and 30 mg long-acting octreotide, given every 4 weeks.
(Sandostatin LAR, 30 mg every 28 days) also failed to reduce IGF-I levels to the normal range. The patient was then treated within a clinical trial with Somavert (pegvisomant) in combination with Sandostatin LAR (30 mg). Treatment with Somavert was initiated at a dose of 10 mg/day s.c. and was adjusted to 15 mg/day because of incomplete suppression of IGF-I. Treatment was well tolerated and resulted in significant improvement of clinical symptoms. The patient reported an improved sense of well-being, disappearance of paresthesias and reduced soft tissue swelling of the hands. Biochemical evaluation demonstrated normalization of IGF-I which was reduced to the age-related reference range.

Eight weeks after the start of treatment we noticed a gradual increase of the transaminases. After ALT increased fivefold above the ULN, which persisted over several weeks, we decided to discontinue treatment with Somavert. Treatment with Sandostatin LAR injections at monthly intervals was continued. γ-GT was only mildly affected. No concurrent increase in serum alkaline phosphatase was observed. Diagnostic work-up for exclusion of other hepatic diseases, including viral hepatitis and haemochromatosis, Wilson’s disease, autoimmune hepatitis and α-1 anti-trypsin deficiency was performed. Ultrasound examination showed normal echogenicity of the liver parenchyma without signs of steatosis. In addition, there was no evidence of gallstone disease. A liver biopsy was performed for further diagnostic evaluation. Histology demonstrated discrete portal fibrosis without bridging and discrete lobular hepatitis with fatty droplets in 30% of hepatocytes. The majority of the portal tracts showed a mixed inflammatory infiltrate and discrete interface hepatitis. Inflammatory cells were composed of lymphocytes, histiocytes, mast cells and eosinophilic granulocytes consistent with chronic mild active hepatitis (Fig. 1 and 2). Two months after discontinuation of

Figure 1 Portal tract (haematoxylin–eosin): mixed portal inflammation with eosinophilic granulocytes and interface hepatitis.

www.eje-online.org
pegvisomant treatment liver transaminases returned to normal values without further specific therapy (Table 2). Gilbert’s syndrome had previously been diagnosed in 1997 in this patient. Interestingly, mild hyperbilirubinaemia, which was present before the increase of the transaminases, normalized during the hepatitis episode and reappeared after transaminases had returned to normal values.

Table 2 Biochemical and hormonal parameters in patient no. 8 before, during and after treatment with pegvisomant.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>January 04</th>
<th>April 04</th>
<th>June 04</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-I (70–230 ng/ml)</td>
<td>556</td>
<td>214</td>
<td>414</td>
</tr>
<tr>
<td>ALT (6–43 U/l)</td>
<td>26</td>
<td>210</td>
<td>32</td>
</tr>
<tr>
<td>AST (11–36 U/l)</td>
<td>26</td>
<td>112</td>
<td>34</td>
</tr>
<tr>
<td>Blood glucose fasting (3.9–6.4 mmol/l)</td>
<td>5.8</td>
<td>5.7</td>
<td>5.3</td>
</tr>
<tr>
<td>Blood glucose 2 h (mmol/l)</td>
<td>6.3</td>
<td>10.2</td>
<td>5</td>
</tr>
<tr>
<td>AUC glucose</td>
<td>15.3</td>
<td>16.9</td>
<td>16.5</td>
</tr>
<tr>
<td>Insulin fasting (µU/ml)</td>
<td>5.47</td>
<td>8.72</td>
<td>3.5</td>
</tr>
<tr>
<td>Insulin 2h (µU/ml)</td>
<td>20.06</td>
<td>108.12</td>
<td>26.5</td>
</tr>
<tr>
<td>AUC insulin</td>
<td>47.7</td>
<td>74.1</td>
<td>60.7</td>
</tr>
<tr>
<td>HOMA (reference 25) (≤ 2)</td>
<td>1.4</td>
<td>2.2</td>
<td>0.8</td>
</tr>
</tbody>
</table>

AUC, area under the curve; HOMA, homeostasis model assessment.
Before commencement of pegvisomant treatment an oral glucose-tolerance test showed completely normal glucose metabolism. During the period of elevation of transaminases we observed an impaired glucose tolerance according to WHO criteria (6) despite normal IGF-I levels (Table 2). Two months after discontinuation of pegvisomant treatment IGF-I levels were again increased twofold above the upper limit and transaminases had returned to normal values. At that time glucose tolerance testing again showed normal results.

Concentrations of haemoglobin A\textsubscript{1c}, cholesterol, triglyceride, lipid electrophoresis, lipoprotein a, C-reactive protein levels, erythrocyte sedimentation rate, haematocrit, white blood cell count, platelet counts, blood urea nitrogen, creatinine and lactate dehydrogenase were within normal limits at baseline and did not change during treatment.

**Discussion**

**Safety and tolerability**

Based on the available data, pegvisomant is well tolerated. In the first two double-blind, placebo-controlled trials of pegvisomant for treatment of acromegaly of 46 and 112 patients, respectively, were randomized (7, 8). Many of the patients from these studies have subsequently been transferred to a long-term daily dosing regimen, with normalization of serum IGF-I in 97% of patients. In these studies, a tenfold increase of ALT and AST was observed in two patients (1.2%). Both patients experienced mild fatigue and had normal bilirubin concentrations. Liver transaminases returned to normal several months after drug discontinuation. In one patient, a liver biopsy was performed revealing chronic active hepatitis of unknown aetiology. The second patient was rechallenged and transaminases rose again, proving a causative role of pegvisomant. No other significant adverse events were observed during long-term treatment (9).

Presently available data showed that the incidence of slight increases of transaminases was not different between pegvisomant- and placebo-treated patients. The increases in transaminases did not appear to be dose-related, usually occurred within 3 month of initiation of therapy and were not associated with any identifiable biochemical, phenotypic or genetic predictors. Concurrent increases in serum total bilirubin and alkaline phosphatase, which are established as indicators of serious drug-induced hepatic injury, were not observed. In many cases, increases in transaminases were sporadic and returned to normal without discontinuation of pegvisomant therapy (10).

The present report adds data from 12 patients treated in Germany with elevations of transaminases to more than three times ULN during pegvisomant treatment. In five of these patients, the presence of sonographically proven gallstone disease together with elevated levels of γ-GT, alkaline phosphatase or bilirubin suggest biliary complications rather than a pegvisomant-induced reaction as the reason for liver enzyme elevations. In two of these patients, cholelithiasis was clearly identified as the reason for liver enzyme elevations: these patients underwent an endoscopic retrograde cholangiography with a therapeutic papillotomy.

After discontinuation of pegvisomant treatment, transaminases returned to normal in all patients. Interestingly, in four patients, transaminases spontaneously normalized despite ongoing treatment with pegvisomant. Additionally, in patients no. 1 and no. 12 treatment was recommenced, after temporary discontinuation of pegvisomant for 3–5 months, and no further increase of transaminases was observed.

The mechanism of pegvisomant-induced deranged transaminases remains the subject of conjecture. In order to increase the antagonist’s half-life and to reduce antibody formation, a pegylated formula of the substance was developed. Hepatotoxicity has not been reported with other pegylated compounds in clinical use, and no such adverse events have been evident in any of the animal toxicology studies to date (11, 12). Moreover, attachment of polyethyleneglycol polymers to polypeptides is thought to reduce immunogenicity. It seems unlikely therefore that the drug formulation of pegvisomant has contributed to the hepatotoxicity observed in our patient.

Gilbert’s syndrome is a benign disorder caused by insufficient enzymatic conjugation of bilirubin without alteration of liver function. Bilirubin levels normalized during the phase of acute hepatitis in the described case. It is unlikely therefore that Gilbert’s syndrome contributed to the development of hepatitis. As induction of enzymes, e.g. by barbiturates, normalizes bilirubin, normalization of bilirubin levels during hepatitis was possibly secondary to inflammation-induced induction of hepatic enzymes.

**Glucose metabolism**

Pegvisomant was not found to induce a glycaemic effect in animal studies (13, 14). Furthermore, in a recent study of healthy subjects, pegvisomant was not associated with deterioration in glucose tolerance (15). GH infusion in normal subjects stimulates gluconeogenesis and lipolysis, which are mediated by the GH receptor, resulting in increased blood glucose and fatty acid levels, causing enhanced insulin secretion and sustained hyperglycaemia (16, 17). Similarly, acromegaly is characterized by increased glucose turnover, insulin resistance and hyperinsulinaemia (18, 19). Adequate control of acromegaly disease activity therefore results in improvement in glucose tolerance by normalization of GH excess.

Van der Lely et al. (9) investigated glucose metabolism in 160 patients treated with pegvisomant. The improvement in serum IGF-I was associated

---

**References**

1. Van der Lely, et al. (9) - glucose metabolism.
2. Safety and tolerability.
3. Discussion.
with a significant fall in mean fasting insulin and glu-
cose, indicating improved insulin sensitivity. These
results were confirmed by Rose & Clemons (20)
who reported a significant progressive increase in
insulin sensitivity, which was related to both dose
and duration of pegvisomant treatment. Improvement
of insulin sensitivity did not appear to be due to
changes in body composition or a reduction of lipoly-
sis respectively (20, 21).

Increased insulin resistance in the case described was
possibly caused by the toxic hepatitis caused by
pegvisomant. Insulin resistance is found in inflamma-
tory liver diseases (22), which are characterized by
increased production of tumour necrosis factor-α
(TNF-α) (23). As TNF-α induces insulin resistance by
directly inhibiting signalling from the insulin receptor
(24), the metabolic changes in this patient are likely to
be primarily related to inflammation-mediated effects.

Conclusion
As pegvisomant is the most effective medical therapy
for normalizing serum IGF-I levels, the drug represents
a major advance in the treatment of acromegaly. Based
on currently available data, pegvisomant is well toler-
ated. However, in a minority of patients increases in
transaminases are observed.

The present series summarizes clinical and labora-
tory data from 12 German patients with elevated
transaminases during pegvisomant treatment. It illus-
trates that in any individual case pegvisomant-induced
abnormalities have to be differentiated from biliary
complications seen in these patients. These may
occur as a consequence of cholecystolithiasis which,
after resumption of normal gall bladder contractility
following discontinuation of long-acting somatostatin
analogue treatment, may be moved into the biliary
tract. The mechanism of pegvisomant-
induced deranged transaminases remains the subject
of conjecture. Because of the low frequency and the
dose independence of the untoward reaction, idiosyn-
cratic drug toxicity has to be assumed. Drug surveil-
ance as well as basic research is needed to clearly
define the association between the use of pegvisomant
and hepatitis. Monitoring of liver transaminases is
required during pegvisomant therapy and, beyond
assessment of ALT and AST, monitoring should
include γ-GT, alkaline phosphatase and potentially
bilirubin levels to facilitate differentiation between
hepatotoxicity and cholestatic causes of transaminase
elevations.

Acknowledgements
The German Pegvisomant Observational Study is
supported by a grant from Pfizer Pharma GmbH
Karlsruhe, Germany.

References
1 Holdaway IM, Rajassorya RC & Gamble GD. Factors influencing
mortality in acromegaly. Journal of Clinical Endocrinology and
Metabolism 2004 89 667–674.
2 Trainer PJ, Drake WM, Perry LA, Taylor NE, Besser GM &
Monson JP. Modulation of cortisol metabolism by the growth
hormone receptor antagonist pegvisomant in patients with
acromegaly. Journal of Clinical Endocrinology and Metabolism
2001 86 2989–2992.
3 Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM &
Trainer PJ. Serum lipoprotein changes following IGF-I normaliza-
tion using a growth hormone receptor antagonist in acromegaly.
Clinical Endocrinology 2002 56 303–311.
4 Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU,
Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D &
Klibanski A. Cardiovascular risk factors in acromegaly before
and after normalization of serum IGF-I levels with the GH antag-
nist pegvisomant. Journal of Clinical Endocrinology and Metabolism
2002 87 1692–1699.
5 Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A & Trainer PJ.
Pegvisomant-induced serum insulin-like growth factor-I normal-
ization in patients with acromegaly returns elevated markers of
bone turnover to normal. Journal of Clinical Endocrinology and
Metabolism 2003 88 5650–5655.
6 World Health Organization. Definition, diagnosis and classification
Organization Consultation, part I: Diagnosis and Classification
7 van der Lely AJ, Lamberts SW, Barkan A, Pandya N, Besser G,
Trainer PJ, Bonert V, Melmed S, Clemons DR, Rose R, Vance ML,
Thormer M, Zib K, Davis RJ, Bennett WF & Scarlett JAA. A
six-week, double blind, placebo controlled study of a growth hor-
mone antagonist B2036–PEG (Trovet®) in acromegalic patients.
Proceedings of the 80th Annual Meeting of the Endocrine Society,
8 Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V,
van der Lely AJ, Dimuraki EV, Stewart PM, Friend KE, Vance ML,
Besser GM, Scarlett JA, Thorne M, Parkinson C, Klibanski A,
Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR,
Clemons DR, Johannsson G, Bengtsson BA, Stavrou S,
Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ,
Hackett S, Zib K, Bennett WF & Davis RJ. Treatment
of acromegaly with the growth hormone-receptor antagon-
1171–1177.
9 van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL,
Katznelson L, Klibanski A, Herman-Bonert V, Melmed S,
Vance ML, Freda PU, Stewart PM, Friend KE, Clemons DR,
Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ,
Hackett S, Zib KA, Davis RJ, Scarlett JA & Thormer M. Long-
term treatment of acromegaly with pegvisomant, a growth hor-
10 CDER. Center for Drug Evaluation and Research Approval Pack-
age for: application number 21–106. Medical review(s) (for peg-
visomant). Center for Drug Evaluation and Research, Food and
11 Drake WM, Parkinson C, Besser GM & Trainer PJ. Clinical use of
a growth hormone receptor antagonist in the treatment of acro-
megaly. Trends in Endocrinology and Metabolism 2001 12
408–413.
12 Harris JM & Chess RB. Effect of pegylation on pharmaceuticals.
13 Flyvbjerg A, Bennett WE, Rasch R, Kopchick JJ & Scarlett JA.
Inhibitory effect of a growth hormone receptor antagonist
(GH20K-PEG) on renal enlargement, glomerular hypertrophy,
and urinary albumin excretion in experimental diabetes in

www.eje-online.org


18 Roelfsema F & Frolich M. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. *Clinical Endocrinology* 1985 **22** 531–537.


Received 5 August 2005
Accepted 25 October 2005